Business
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
Salix Pharmaceuticals Releases Third Annual Patient Perspectives Report LAVAL, QC / ACCESSWIR...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare ProviderSalix Pharmaceuticals Releases Third Annual Patient Perspectives ReportLAVAL, QC / ACCESSWIRE / April 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). The report, Patient Perspectives: Impacts of Living with IBS, offers a current understanding of the behaviors and experiences of the IBS and CIC patient population, including insights on diagnosis, barriers to provider discussions, and symptom management.The report, which was developed based on a nationwide survey conducted in partnership with the Fairleigh Dickinson University Poll in January 2023, found most notably that more than half of survey respondents (54%) waited 1 year or more before mentioning their symptoms to healthcare providers. Additionally, many were unaware that IBS was a chronic condition (43%), assumed their symptoms would resolve with diet modification (43%), over-the-counter medications (39%), or felt awkward talking about their symptoms to their doctor (32%).\"The findings from this year's survey demonstrate the need for continued awareness and education about the multiple symptoms associated with IBS and CIC, which are chronic conditions that have prescription treatment options available. It also underscores the need for a more proactive HCP-patient dialogue around IBS symptoms,\" said Nicola Kayel, Vice President, GI Marketing. \"With IBS affecting between 25 and 45 million people in the United States1, Salix remains steadfast in its commitment to encourage meaningful provider-patient interactions that open the lines of communications to a collaborative approach to symptom management and guideline-based treatments.\"Additional key findings from the report include:Overall, 1 out of 5 (23%) adult patients were not aware that there were prescription treatment options available to address their IBS symptomsOnly 30% of IBS-diagnosed survey respondents reported that they were initially offered a prescriptionSurprisingly, more than one-quarter o...